Nasdaq
$1.55▼ 1.90%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $228.3MShares out 1.500M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 2d agoAfter-hours26.10.23 05:056-KKey event#●●●#●●●
InflaRx N.V.
InflaRx presented new pre-clinical data for its oral C5aR inhibitor, izicopan, at the American Society of Nephrology’s Kidney Week 2026. The data demonstrated that izicopan robustly inhibits renal injury and inflammatory responses, while structural modeling highlights its differentiated molecular profile with a lower potential for drug-drug interactions compared to existing therapies.…more
$1.55-1.90%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.17After-hours26.08.18 05:34SCHEDULE 13GOwnership
InflaRx N.V.
Commodore Capital LP and associated entities have entered into a joint filing agreement to report their beneficial ownership in InflaRx N.V. (IFRX). Dated August 17, 2026, the agreement stipulates that all parties are collectively responsible for the timely and accurate filing of subsequent Schedule 13G amendments.…more
$1.55-1.90%vs prev closeView filingShare - 8.13Pre-market26.08.13 13:15filedEFFECTOther
InflaRx N.V.
InflaRx N.V. received notice of effectiveness from the SEC for its registration statement (File No. 333-298039) on August 12, 2026. This approval officially authorizes the company to proceed with the securities offering and capital raising activities associated with the filing.…more
$1.55-1.90%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoRegular26.10.23 01:00#●●●#●●●
InflaRx Presents Pre-clinical Data for Izicopan in Kidney Disease
InflaRx announced new pre-clinical data demonstrating the renal protective potential of its therapeutic candidate, izicopan, in kidney disease models. As these results are based on early-stage research, further clinical development is required to validate its therapeutic efficacy.…more
$1.55-1.90%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.2Pre-market26.10.02 20:30
●●●●●●●● ●●●●● ●●●●●●
InflaRx will present late-breaking pre-clinical data for its kidney disease candidate, izicopan, at the upcoming Kidney Week 2026 conference. This presentation focuses on research findings and does not represent a commercial milestone or contract win.…more
$1.55-1.90%vs prev close - 10.1Pre-market26.10.01 20:30
●●●●●●●● ●●●●● ●●●●●●
InflaRx has appointed Dr. Gabriela Alperovich, a veteran in renal disease and clinical development, as its new Senior Vice President and Global Head of Clinical Development. This leadership addition aims to accelerate the development of the company's lead pipeline candidate, izicopan.…more
$1.55-1.90%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report